Astrazeneca PLC ORD SHS $0.25
Astrazeneca PLC ORD SHS $0.25/ GB0009895292 /
AZN
|
10/05/2024 17:51:25
|
Chg.
+38.0000
|
Volume |
Bid18:30:00 |
Demandez à18:30:00 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
|
12,370.0000GBX
|
+0.31%
|
1.41 Mio.
Chiffrre d'affaires(GBP): 124.29 Mio. |
11,500.0000Bid taille: 4,000 |
12,470.0000Ask la taille: 500 |
191.76 Mrd.GBP |
- |
- |
Description de l'entreprise
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Conseil d'administration & Conseil de surveillance
| PDG |
| Pascal Soriot |
| Conseil d'administration |
| Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
| Conseil de surveillance |
| Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |
Données de l'entreprise
| Nom: |
AstraZeneca plc |
| Adresse: |
1 Francis Crick Avenue Cambridge Biomedical Campus,Cambridge, CB2 0AA United Kingdom |
| Téléphone: |
0800 783 0033 |
| Fax: |
+44-20-7604-8151 |
| Courriel: |
Medical.InformationU...eca.com
Medical.InformationUK@astrazeneca.com
|
| Internet: |
www.astrazeneca.com |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
06/04/1999 |
Calendrier de l'entreprise
|
CW 30 | 25/07/2024
Interim Report 2nd Quarter/6 Months
|
|
CW 32 | 08/08/2024
Ex-Dividend
|
|
CW 32 | 09/08/2024
Record Date
|
|
CW 37 | 09/09/2024
Dividend Payment
|
|
CW 46 | 12/11/2024
Interim Report 3rd Quarter/9 Months
|
